Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 4/20 | 0.50 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.37 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.37 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.37 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | NQO2 | P16083 | 3/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | BAD | Q92934 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30507560 | 0.75 | AOC3 (0.50) | AOC3TXNRD1TXNRD3TXNRD2ABCG2 | |
| SCHEMBL4031896 | 0.75 | AOC3 (0.50) | AOC3TXNRD1TXNRD3TXNRD2ABCG2 | |
| SCHEMBL1768456 | 0.75 | AOC3 (0.50) | AOC3TXNRD1TXNRD3TXNRD2ABCG2 | |
| SCHEMBL12865263 | 0.75 | AOC3 (0.50) | AOC3TXNRD1TXNRD3TXNRD2ABCG2 | |
| SCHEMBL4493536 | 0.75 | AOC3 (0.50) | AOC3TXNRD1TXNRD3TXNRD2ABCG2 | |
| SCHEMBL8468090 | 0.74 | AOC3 (0.49) | AOC3TXNRD1TXNRD3TXNRD2ABCG2 | |
| SCHEMBL863397 | 0.72 | AOC3 (0.51) | AOC3TXNRD1TXNRD3TXNRD2ABCG2 | |
| SCHEMBL17522052 | 0.71 | AOC3 (0.63) | AOC3TXNRD1TXNRD3TXNRD2ABCG2 | |
| SCHEMBL16793055 | 0.71 | AOC3 (0.46) | AOC3TXNRD1TXNRD3TXNRD2ABCG2 | |
| SCHEMBL13748595 | 0.71 | AOC3 (0.46) | AOC3TXNRD1TXNRD3TXNRD2ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041690-A1 | Co-Administration of Dopamine-Receptor Binding Compounds | DARPHARMA, INC. | 2010-02-18 | — | — | US | disclosed |
| US-20070254906-A1 | Method of Administration of Dopamine Receptor Agonists | DARPHARMA, INC. (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070155720-A1 | Co-administration of dopamine-receptor binding compounds | DARPHARMA, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| EP-1414457-B1 | CHIRAL DINAPSOLINE | PURDUE RESEARCH FOUNDATION (US) | 2007-06-20 | — | — | EP | disclosed |
| EP-1320367-A4 | PROCESS FOR THE PREPARATION OF DINAPSOLINE | PURDUE RESEARCH FOUNDATION (US) | 2007-01-17 | — | — | EP | disclosed |
| EP-1699450-A2 | CO-ADMINISTRATION OF DOPAMINE-RECEPTOR BINDING COMPOUNDS | Darpharma, INC. (US) | 2006-09-13 | — | — | EP | disclosed |
| US-7091212-B2 | Chiral dinapsoline | PURDUE RESEARCH FOUNDATION (US) | 2006-08-15 | — | — | US | disclosed |
| WO-2006012640-A2 | METHOD OF ADMINISTRATION OF DOPAMINE RECEPTOR AGONISTS | DARPHARMA, INC. (US) | 2006-02-02 | — | — | WO | disclosed |
| WO-2005062894-A2 | CO-ADMINISTRATION OF DOPAMINE-RECEPTOR BINDING COMPOUNDS | DARPHARMA, INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| EP-1414457-A4 | CHIRAL DINAPSOLINE | PURDUE RESEARCH FOUNDATION (US) | 2004-12-29 | — | — | EP | disclosed |
| EP-1414457-A1 | CHIRAL DINAPSOLINE | PURDUE RESEARCH FOUNDATION (US) | 2004-05-06 | — | — | EP | disclosed |
| US-20040063741-A1 | Chiral dinapsoline | SIT SING-YUEN (US) | 2004-04-01 | — | — | US | disclosed |
| US-6645975-B1 | Reducing, deprotecting and optionally alkylating chemical intermediates to form 8,9-dihydroxy-2,3,7,11b-tetrahydro-1H-naphtho(1,2,3-de)isoquinoline, used as dopamine receptor agonists | PURDUE RESEARCH FOUNDATION | 2003-11-11 | — | — | US | disclosed |
| EP-1320367-A1 | PROCESS FOR THE PREPARATION OF DINAPSOLINE | PURDUE RESEARCH FOUNDATION (US) | 2003-06-25 | — | — | EP | disclosed |
| WO-2003013532-A1 | CHIRAL DINAPSOLINE | PURDUE RESEARCH FOUNDATION (US) | 2003-02-20 | — | — | WO | disclosed |
| WO-2002013827-A1 | PROCESS FOR THE PREPARATION OF DINAPSOLINE | PURDUE RESEARCH FOUNDATION (US) | 2002-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041690-A1 | Co-Administration of Dopamine-Receptor Binding Compounds | DRD2, DRD1, DRD3 | AOC3 1441/4885TXNRD1 1156/4885TXNRD3 1308/4885 |
| US-20070254906-A1 | Method of Administration of Dopamine Receptor Agonists | ADRA1D, DRD2, CHRM3 | AOC3 1193/4885TXNRD1 612/4885TXNRD3 933/4885 |
| US-20040063741-A1 | Chiral dinapsoline | NAP1L1, DDAH1, NAP1L4 | AOC3 1362/4885TXNRD1 3708/4885TXNRD3 3659/4885 |
| US-20070155720-A1 | Co-administration of dopamine-receptor binding compounds | DRD2, DRD1, DRD3 | AOC3 1418/4885TXNRD1 1159/4885TXNRD3 1313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.